Trevi Therapeutics (TRVI) said Monday a phase 2a trial of its investigational drug Haduvio met the primary endpoint of a statistically significant reduction in 24-hour cough frequency in patients with refractory chronic cough.
The company said Haduvio, or oral nalbuphine ER, achieved a reduction in 24-hour cough count of 67% from baseline and 57% on a placebo-adjusted basis at day 21.
Trevi said it plans to discuss the next steps with the US Food and Drug Administration and expects to initiate the next study after receiving the regulator's feedback.
Shares of the company rose more than 32% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.